Wed, Dec 24, 2014, 8:05 PM EST - U.S. Markets closed early today

Recent

% | $
Quotes you view appear here for quick access.

Muscle Pharm Corp. Message Board

  • andy3d2014 andy3d2014 Jun 28, 2014 10:27 AM Flag

    mslp more shareholder friendly and getting the up-listing done

    This is great step forward towards making mslp more shareholder friendly and getting the up-listing done.

    Effective June 23, 2014, the Board of Directors of MusclePharm Corporation, a Nevada corporation ("MusclePharm" or the “Company”), appointed Gregory Macosko to serve as a member of the Company’s Board of Directors and as Chairman of the Company’s Audit Committee. The Board of Directors has determined that Mr. Macosko is (i) an independent director pursuant to the rules of the NASDAQ Stock Market, and (ii) an “audit committee financial expert” as such term is defined in Item 407(d) of Regulation S-K promulgated by the Securities and Exchange Commission (the “SEC”).

    Gregory Macosko is currently a member of the Board of Directors of Montrose Advisors, and an SEC-registered investment advisor. He also serves as a business advisor to the Board of Directors of Bioxiness Pharmaceuticals, a California-based pre-clinical stage company. In September of 2013, Mr. Macosko retired as a Partner from Lord Abbett & Co., a privately held investment management firm. He was a Portfolio Manager of Lord Abbet's Small Cap Value Fund and a founding member of the company’s Proxy Committee. Mr. Macosko is a Phi Beta Kappa graduate of Albion College, a Fulbright Scholar in Germany, and holds an MBA from Columbia University. His twenty-four years of experience on Wall Street bring to MusclePharm broad knowledge of public company management, and investment community relationships among institutional investors, analysts and investment bankers.

    Sentiment: Buy

 
MSLP
8.7501-0.0499(-0.57%)Dec 24 12:49 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.